These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 32046364

  • 1. Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy.
    Moodley T, Singh M.
    Molecules; 2020 Feb 08; 25(3):. PubMed ID: 32046364
    [Abstract] [Full Text] [Related]

  • 2. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
    Zhang Q, Zhao H, Li D, Liu L, Du S.
    Colloids Surf B Biointerfaces; 2017 Jan 01; 149():138-145. PubMed ID: 27750088
    [Abstract] [Full Text] [Related]

  • 3. Amphiphilic hyperbranched polyester coated rod mesoporous silica nanoparticles for pH-responsive doxorubicin delivery.
    Bafkary R, Ahmadi S, Fayazi F, Karimi M, Fatahi Y, Ebrahimi SM, Atyabi F, Dinarvand R.
    Daru; 2020 Jun 01; 28(1):171-180. PubMed ID: 32006342
    [Abstract] [Full Text] [Related]

  • 4. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
    Tam YT, To KK, Chow AH.
    Colloids Surf B Biointerfaces; 2016 Mar 01; 139():249-58. PubMed ID: 26724466
    [Abstract] [Full Text] [Related]

  • 5. Hybrid mesoporous silica nanospheres modified by poly (NIPAM-co-AA) for drug delivery.
    Zhang K, Zhou D, Wang Z, Zhang Y, He P.
    Nanotechnology; 2019 Aug 30; 30(35):355604. PubMed ID: 31071691
    [Abstract] [Full Text] [Related]

  • 6. Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery.
    Al-Nadaf AH, Dahabiyeh LA, Jawarneh S, Bardaweel S, Mahmoud NN.
    Pharm Dev Technol; 2021 Jun 30; 26(5):582-591. PubMed ID: 33729906
    [Abstract] [Full Text] [Related]

  • 7. Redox-responsive nanocarriers for drug and gene co-delivery based on chitosan derivatives modified mesoporous silica nanoparticles.
    Lin JT, Liu ZK, Zhu QL, Rong XH, Liang CL, Wang J, Ma D, Sun J, Wang GH.
    Colloids Surf B Biointerfaces; 2017 Jul 01; 155():41-50. PubMed ID: 28407530
    [Abstract] [Full Text] [Related]

  • 8. Superior doxorubicin cellular delivery effect established by optically active mesoporous silica nanoparticles.
    Wang L, Yu D, Li D, Li J.
    Drug Deliv Transl Res; 2024 Nov 01; 14(11):3163-3172. PubMed ID: 38381319
    [Abstract] [Full Text] [Related]

  • 9. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
    Zhang Q, Chen X, Shi H, Dong G, Zhou M, Wang T, Xin H.
    Colloids Surf B Biointerfaces; 2017 Dec 01; 160():527-534. PubMed ID: 29024917
    [Abstract] [Full Text] [Related]

  • 10. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X, Cao X, Zhang H.
    Mater Sci Eng C Mater Biol Appl; 2018 Mar 01; 84():108-117. PubMed ID: 29519418
    [Abstract] [Full Text] [Related]

  • 11. Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance.
    Shao M, Chang C, Liu Z, Chen K, Zhou Y, Zheng G, Huang Z, Xu H, Xu P, Lu B.
    Colloids Surf B Biointerfaces; 2019 Nov 01; 183():110427. PubMed ID: 31408782
    [Abstract] [Full Text] [Related]

  • 12. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
    Shen Y, Li M, Liu T, Liu J, Xie Y, Zhang J, Xu S, Liu H.
    Int J Nanomedicine; 2019 Nov 01; 14():4029-4044. PubMed ID: 31213813
    [Abstract] [Full Text] [Related]

  • 13. pH and Ultrasound Dual-Responsive Polydopamine-Coated Mesoporous Silica Nanoparticles for Controlled Drug Delivery.
    Li X, Xie C, Xia H, Wang Z.
    Langmuir; 2018 Aug 28; 34(34):9974-9981. PubMed ID: 30056720
    [Abstract] [Full Text] [Related]

  • 14. Poly(amino acid)/ZnO/mesoporous silica nanoparticle based complex drug delivery system with a charge-reversal property for cancer therapy.
    Kuang Y, Chen H, Chen Z, Wan L, Liu J, Xu Z, Chen X, Jiang B, Li C.
    Colloids Surf B Biointerfaces; 2019 Sep 01; 181():461-469. PubMed ID: 31176118
    [Abstract] [Full Text] [Related]

  • 15. A chitosan/mesoporous silica nanoparticle-based anticancer drug delivery system with a "tumor-triggered targeting" property.
    Liao T, Liu C, Ren J, Chen H, Kuang Y, Jiang B, Chen J, Sun Z, Li C.
    Int J Biol Macromol; 2021 Jul 31; 183():2017-2029. PubMed ID: 34097958
    [Abstract] [Full Text] [Related]

  • 16. Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery.
    He Y, Luo L, Liang S, Long M, Xu H.
    J Biomater Appl; 2017 Oct 31; 32(4):524-532. PubMed ID: 28776488
    [Abstract] [Full Text] [Related]

  • 17. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
    Xie X, Li F, Zhang H, Lu Y, Lian S, Lin H, Gao Y, Jia L.
    Eur J Pharm Sci; 2016 Feb 15; 83():28-35. PubMed ID: 26690044
    [Abstract] [Full Text] [Related]

  • 18. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
    Bagheri E, Alibolandi M, Abnous K, Taghdisi SM, Ramezani M.
    J Mater Chem B; 2021 Feb 15; 9(5):1351-1363. PubMed ID: 33447840
    [Abstract] [Full Text] [Related]

  • 19. Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy.
    Lohiya G, Katti DS.
    Carbohydr Polym; 2022 Feb 01; 277():118822. PubMed ID: 34893239
    [Abstract] [Full Text] [Related]

  • 20. Amine-functionalized mesoporous silica nanoparticles decorated by silver nanoparticles for delivery of doxorubicin in breast and cervical cancer cells.
    Ghobadi M, Salehi S, Ardestani MTS, Mousavi-Khattat M, Shakeran Z, Khosravi A, Cordani M, Zarrabi A.
    Eur J Pharm Biopharm; 2024 Aug 01; 201():114349. PubMed ID: 38848782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.